THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ: AMGN) today announced its intent to comply with the Pharmaceutical Research and Manufacturers of America’s (PhRMA) revised “Code on Interactions with U.S. Healthcare Professionals.” The company’s announcement of its voluntary support for the Code is the latest element of Clearly Amgen, the company’s ongoing initiative to provide clear communications about and easy access to Amgen’s policies and practices on ethical research, clinical data disclosure, responsible marketing and other topics of interest to Amgen stakeholders.
